Header Logo

Connection

JOSEPH JANKOVIC to Retrospective Studies

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Retrospective Studies.
JOSEPH JANKOVIC
Connection Strength
1.069
Retrospective Studies
  1. Axial tics in Tourette syndrome and chronic tic disorders. J Neurol. 2024 Nov; 271(11):7232-7238.
    View in: PubMed
    Score: 0.062
  2. Medication refractory restless legs syndrome: Real-world experience. J Neurol Sci. 2024 Aug 15; 463:123121.
    View in: PubMed
    Score: 0.061
  3. Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol. 2023 Sep; 270(9):4518-4522.
    View in: PubMed
    Score: 0.057
  4. The Clinical Value of Patient Home Videos in Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2021; 11:37.
    View in: PubMed
    Score: 0.050
  5. Phenotypic Features of Isolated Essential Tremor, Essential Tremor Plus, and Essential Tremor-Parkinson's Disease in a Movement Disorders Clinic. Tremor Other Hyperkinet Mov (N Y). 2021 03 29; 11:12.
    View in: PubMed
    Score: 0.049
  6. Botulinum Neurotoxin Injections in Childhood Opisthotonus. Toxins (Basel). 2021 02 12; 13(2).
    View in: PubMed
    Score: 0.048
  7. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
    View in: PubMed
    Score: 0.042
  8. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018 07 19; 10(7).
    View in: PubMed
    Score: 0.040
  9. Functional (psychogenic) stereotypies. J Neurol. 2017 Jul; 264(7):1482-1487.
    View in: PubMed
    Score: 0.038
  10. Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. J Neurol Neurosurg Psychiatry. 2017 05; 88(5):453-455.
    View in: PubMed
    Score: 0.036
  11. Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. J Neurol. 2017 Feb; 264(2):359-363.
    View in: PubMed
    Score: 0.036
  12. Psychogenic Ophthalmologic Movement Disorders. J Neuropsychiatry Clin Neurosci. 2016; 28(3):195-8.
    View in: PubMed
    Score: 0.034
  13. Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015 Nov; 262(11):2420-4.
    View in: PubMed
    Score: 0.033
  14. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014 Nov; 90:344-8.
    View in: PubMed
    Score: 0.031
  15. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan; 29(1):126-30.
    View in: PubMed
    Score: 0.029
  16. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011 Sep; 17(8):625-8.
    View in: PubMed
    Score: 0.025
  17. Tourette's syndrome in adults. Mov Disord. 2010 Oct 15; 25(13):2171-5.
    View in: PubMed
    Score: 0.024
  18. Hemidystonia-hemiatrophy syndrome. Mov Disord. 2009 Mar 15; 24(4):583-9.
    View in: PubMed
    Score: 0.021
  19. Psychogenic movement disorders in children. Mov Disord. 2008 Oct 15; 23(13):1875-81.
    View in: PubMed
    Score: 0.021
  20. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008 Aug; 14(4):253-4.
    View in: PubMed
    Score: 0.020
  21. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008 Mar; 48(3):379-84.
    View in: PubMed
    Score: 0.020
  22. Malignant Tourette syndrome. Mov Disord. 2007 Sep 15; 22(12):1743-50.
    View in: PubMed
    Score: 0.019
  23. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007 Oct; 13(7):411-6.
    View in: PubMed
    Score: 0.019
  24. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007 Apr; 106(4):621-5.
    View in: PubMed
    Score: 0.018
  25. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15; 22(2):193-7.
    View in: PubMed
    Score: 0.018
  26. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006 Sep 26; 67(6):1083-5.
    View in: PubMed
    Score: 0.018
  27. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006 Sep-Oct; 29(5):259-64.
    View in: PubMed
    Score: 0.018
  28. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Sep; 12(6):382-7.
    View in: PubMed
    Score: 0.017
  29. Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2025; 15:26.
    View in: PubMed
    Score: 0.016
  30. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005 Mar; 20(1):44-7.
    View in: PubMed
    Score: 0.016
  31. Secondary paroxysmal dyskinesias. Mov Disord. 2002 Jul; 17(4):726-34.
    View in: PubMed
    Score: 0.013
  32. Hold that pose: capturing cervical dystonia's head deviation severity from video. Ann Clin Transl Neurol. 2022 05; 9(5):684-694.
    View in: PubMed
    Score: 0.013
  33. Dystonia in corticobasal degeneration. Mov Disord. 2001 Mar; 16(2):252-7.
    View in: PubMed
    Score: 0.012
  34. Head tremor and pain in cervical dystonia. J Neurol. 2021 May; 268(5):1945-1950.
    View in: PubMed
    Score: 0.012
  35. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999 Jan; 56(1):98-102.
    View in: PubMed
    Score: 0.010
  36. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 01; 74(2):216-224.
    View in: PubMed
    Score: 0.009
  37. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10; 88(2):152-159.
    View in: PubMed
    Score: 0.009
  38. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015 Jul; 14(7):710-9.
    View in: PubMed
    Score: 0.008
  39. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
    View in: PubMed
    Score: 0.008
  40. Vascular progressive supranuclear palsy. J Neural Transm Suppl. 1994; 42:189-201.
    View in: PubMed
    Score: 0.007
  41. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993 May; 43(5):937-41.
    View in: PubMed
    Score: 0.007
  42. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012; 90(5):300-6.
    View in: PubMed
    Score: 0.007
  43. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008 Nov 15; 23(15):2194-201.
    View in: PubMed
    Score: 0.005
  44. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009 May; 71(5):551-8.
    View in: PubMed
    Score: 0.005
  45. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007; 149(9):857-66; discussion 866.
    View in: PubMed
    Score: 0.005
  46. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol. 1999 Jan; 56(1):90-4.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.